PIK3CA and neoplasm: The dual inhibition of the BRAF/MEK and PI3K signaling pathways has been shown to substantially improve anti-tumor activity in different tumor types, essentially by inhibiting cross talks between the two pathways, which are responsible for resistance mechanisms [36].